It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by significant and complex genetic etiology. GWAS studies have identified genetic variants associated with ASD, but the functional impacts of these variants remain unknown. Here, we integrated four distinct levels of biological information (GWAS, eQTL, spatial genome organization and protein–protein interactions) to identify potential regulatory impacts of ASD-associated SNPs (p < 5 × 10–8) on biological pathways within fetal and adult cortical tissues. We found 80 and 58 SNPs that mark regulatory regions (i.e. expression quantitative trait loci or eQTLs) in the fetal and adult cortex, respectively. These eQTLs were also linked to other psychiatric disorders (e.g. schizophrenia, ADHD, bipolar disorder). Functional annotation of ASD-associated eQTLs revealed that they are involved in diverse regulatory processes. In particular, we found significant enrichment of eQTLs within regions repressed by Polycomb proteins in the fetal cortex compared to the adult cortex. Furthermore, we constructed fetal and adult cortex-specific protein–protein interaction networks and identified that ASD-associated regulatory SNPs impact on immune pathways, fatty acid metabolism, ribosome biogenesis, aminoacyl-tRNA biosynthesis and spliceosome in the fetal cortex. By contrast, in the adult cortex they largely affect immune pathways. Overall, our findings highlight potential regulatory mechanisms and pathways important for the etiology of ASD in early brain development and adulthood. This approach, in combination with clinical studies on ASD, will contribute to individualized mechanistic understanding of ASD development.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Auckland, Liggins Institute, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343)
2 University of Auckland, Liggins Institute, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343); University of Auckland, Maurice Wilkins Centre, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343)
3 University of Auckland, School of Medical Science, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343)
4 University of Auckland, School of Population Health, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343)
5 University of Auckland, Liggins Institute, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343); University of Auckland, Maurice Wilkins Centre, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343); University of Auckland, Brain Research New Zealand, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343); University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297); Garvan Institute of Medical Research, Sydney, Australia (GRID:grid.415306.5) (ISNI:0000 0000 9983 6924)